Uncategorized
FDA approves Lucentis for diabetic retinopathy in patients with diabetic macular edema
The FDA today announced the expanded approval of Lucentis 0.3 mg for the treatment of diabetic retinopathy in patients with diabetic macular edema, according to a news release from the agency.Administered by a physician as an injection into the eye once a month, Lucentis (ranibizumab, Genentech) should be used alongside appropriate treatments to manage blood pressure, blood sugar and cholesterol.